United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer said on Tuesday its chief scientific officer Mikael Dolsten, a key figure behind the development of the company's COVID-19 vaccine, would step down after a more than 15-year career at the drugmaker.

Pfizer's longtime science chief Mikael Dolsten to step down

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the company is launching the process to identify a successor for Dr. Mikael Dolsten, Pfizer's Chief Scientific Officer and President, Pfizer Research & Development, who will depart the company after a more than 15-year stellar career. This process is expected to last several months, probably through early next year. Pfizer will initiate an external search for a new Chief Scientific Officer, and Dr. Dolsten will assist i.

Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development

Pfizer (PFE) concluded the recent trading session at $27.93, signifying a -0.43% move from its prior day's close.

Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade

Pfizer's respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a higher risk of pre-term or early births, according to a study published on Monday that analyzed real-world use of the shots.

Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births

Pfizer's recent financial performance and Wall Street analysts' expectations around the upcoming quarterly earnings release suggest that we are currently at an inflection point. The company's current pipeline of new product developments looks promising, and two recent FDA approvals underscore its ability to deliver new products to the market. I expect more full-year EPS guidance upgrades soon, as it appears that the company is moving ahead of management's initial cost-cutting plans.

Pfizer: The Inflection Point Is Here

Much of Pfizer's revenue is driven by therapies with only modest competition. This stock is also developing a very impressive dividend-growth track record.

Want $1,000 in Dividend Income? Here's How Much You Have to Invest in Pfizer Stock

Despite a tanking stock price, Pfizer has raised its dividend for 15 consecutive years. Pfizer's profits are off their peak but more than sufficient to continue raising the dividend.

Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?

CVS Health

Walgreens

Uncovering bargain stocks poised for substantial growth is hard. Understanding which stocks to buy can significantly impact investment success as the world navigates through the complexities of market trends and economic landscapes.

3 Bargain Stocks With the Potential for Mind-Boggling Returns

Ares Capital

Bristol-Myers

Pfizer's been raising its dividend payout for 15 years, and a heap of new products could help it continue the streak. The largest publicly traded business development company, Ares Capital offers investors a yield above 9% at recent prices.

3 Reliable Dividend Stocks With Yields Above 5% You Can Buy With $100 in July

Alibaba

PayPal

Despite their recent struggles, these three industry giants hold the promise of significant upside. With favorable consensus price targets and ratings, attractive P/E valuations, solid earnings growth projections, and some highly attractive dividend yields, they present a hopeful picture for income and value-oriented investors.

3 Stock Giants Analysts Are Bullish On Despite Struggles

AT&T

Verizon

24/7 Insights Wounded blue chip stocks can offer huge total return potential.

Jump on These 5 Ultra-High-Yield Pound-the-Table Stock Buys Now

Agree Realty

Rithm Capital Corp

Real estate investment trust Agree Realty isn't nearly as risky as it seems with just a superficial glance. Pharmaceutical giant Pfizer isn't the powerhouse it used to be, but what it lacks in firepower, it more than makes up for in reliable revenue.

3 Dividend Stocks That Are Screaming Buys in July

Cisco Systems

Enbridge

Realty Income Corp

First half of 2024 is profitable for investors, S&P 500 up 14.48% and Dividend Harvesting Portfolio ROI at 14.05%. Market outlook positive with Fed rate cuts expected, unemployment increase may signal recession. Portfolio generates $1,552.82 in forward dividend income, focusing on diversification and income growth.

Dividend Harvesting Portfolio Week 174: $17,400 Allocated, $1,552.82 In Projected Dividends

Crown Castle International

Chevron

Altria

Philip Morris

Today, we will discuss juicy long-term dividend growth stocks that have grown for over a decade. It's fairly easy to find stocks that have continuously grown dividends over the past decade.

7 Juicy Dividend Stocks That Have Grown for More Than a Decade

Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.

Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?

Southwest Airlines

MongoDB

When it rains, it pours. However, the storm will eventually pass.

3 Undervalued Stocks Poised for a Jaw-Dropping Breakout

Pharmaceutical giant Pfizer Inc. NYSE: PFE has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S NYSE: NVO and Mounjaro and Zepbound makers Eli Lilly & Co. NYSE: LLY. Pfizer had failed in its previous attempts to create a viable GLP-1 contender.

Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes

Pfizer is in the midst of transition as it faces multiple patent cliffs. The company's growth strategy suggests that the business could be bigger by the end of the decade, but not necessarily by a whole lot.

1 Underwhelming Stat That May Have You Thinking Twice About Buying Pfizer's Stock

AbbVie

Vertex Pharmaceuticals

One of the most important sectors in any country's economy is the biotech sector. Picking under-the-radar biotech stocks is easier said than done because we do not see immediate results.

3 Under-the-Radar Biotech Stocks With Blockbuster Potential

Moderna

London's High Court on Tuesday ruled that one of Moderna's patents relating to technology key to the development of vaccines for COVID-19 was invalid, but that another was valid and had been infringed by Pfizer and BioNTech's rival vaccine.

UK court gives mixed ruling in Pfizer v Moderna COVID vaccine patents case

Dividend stocks have a knack for running circles around non-payers over the long run. An industry-leading real estate investment trust (REIT), which has raised its payout for 107 consecutive quarters, has reached a 6% yield and is primed to be bought by opportunistic investors.

Time to Pounce: 2 Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought for the Second Half of 2024 (and Beyond)

When excluding sales Pfizer generated due to COVID-19 vaccines and medication, the business is reporting solid growth. Especially the oncology business will drive growth in the years to come, and the Seagan acquisition might also contribute. With its high dividend yield and rather undervalued stock, PFE stock is a "Buy" at this point.

Pfizer: It Could Be A Bargain

British American Tobacco

Comcast

Campbell Soup

Dow Inc

Duke Energy

Gilead Sciences

Johnson & Johnson

Kinder Morgan

Medtronic

Polaris

PNC Financial Services

Morningstar published 10 Best Value Stocks to Buy for the Long Term, undervalued blue-chip stocks with low price to fair value. Valuation and future return of each stock analyzed, compared to the S&P 500, Bristol-Myers has the highest potential rate of return. In comparison to Morningstar's 10 Best Value Stocks with 10 Best Dividend Stocks, Bristol-Myers stands out as undervalued with a high potential return.

Going Beyond Morningstar's 10 Best Value Stocks List

News for Pfizer Stock (PFE)